Bank of New York Mellon’s PDL BioPharma, Inc. PDLI Stock Holding History

Bank of New York Mellon’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-486,929	Closed	-$1.53M	–	4314
2020 Q3	$1.53M	Sell	486,929 -21,575	-4%	-$68.9K	﹤0.01%	2834
2020 Q2	$1.48M	Sell	508,504 -1,059	-0.2%	-$3.35K	﹤0.01%	2866
2020 Q1	$1.44M	Sell	509,563 -47,797	-9%	-$154K	﹤0.01%	2729
2019 Q4	$1.81M	Sell	557,360 -34,381	-6%	-$99.8K	﹤0.01%	2872
2019 Q3	$1.28M	Sell	591,741 -66,055	-10%	-$177K	﹤0.01%	3028
2019 Q2	$2.07M	Sell	657,796 -64,198	-9%	-$208K	﹤0.01%	2782
2019 Q1	$2.69M	Sell	721,994 -1,120	-0.2%	-$3.78K	﹤0.01%	2630
2018 Q4	$2.1M	Sell	723,114 -595,531	-45%	-$1.64M	﹤0.01%	2698
2018 Q3	$3.47M	Buy	1,318,645 +35,617	+3%	+$87.4K	﹤0.01%	2566
2018 Q2	$3M	Buy	1,283,028 +8,036	+0.6%	+$22.4K	﹤0.01%	2640
2018 Q1	$3.75M	Sell	1,274,992 -10,354	-0.8%	-$28.3K	﹤0.01%	2493
2017 Q4	$3.52M	Sell	1,285,346 -807,975	-39%	-$2.48M	﹤0.01%	2528
2017 Q3	$7.1M	Sell	2,093,321 -28,551	-1%	-$79.4K	﹤0.01%	2171
2017 Q2	$5.24M	Sell	2,121,872 -5,779	-0.3%	-$13.3K	﹤0.01%	2314
2017 Q1	$4.83M	Buy	2,127,651 +135,386	+7%	+$299K	﹤0.01%	2343
2016 Q4	$4.22M	Buy	1,992,265 +434,301	+28%	+$1.21M	﹤0.01%	2416
2016 Q3	$5.22M	Sell	1,557,964 -2,058,914	-57%	-$6.54M	﹤0.01%	2220
2016 Q2	$11.4M	Buy	3,616,878 +209,854	+6%	+$700K	﹤0.01%	1784
2016 Q1	$11.3M	Buy	3,407,024 +53,121	+2%	+$166K	﹤0.01%	1759
2015 Q4	$11.9M	Buy	3,353,903 +608,476	+22%	+$2.55M	﹤0.01%	1739
2015 Q3	$13.8M	Sell	2,745,427 -184,003	-6%	-$1.05M	﹤0.01%	1668
2015 Q2	$18.8M	Buy	2,929,430 +127,977	+5%	+$857K	0.01%	1527
2015 Q1	$19.7M	Sell	2,801,453 -12,579,229	-82%	-$91.1M	0.01%	1505
2014 Q4	$119M	Buy	15,380,682 +146,846	+1%	+$1.16M	0.03%	530
2014 Q3	$114M	Buy	15,233,836 +31,965	+0.2%	+$297K	0.03%	526
2014 Q2	$147M	Sell	15,201,871 -564,985	-4%	-$5.04M	0.04%	455
2014 Q1	$131M	Buy	15,766,856 +205,077	+1%	+$1.76M	0.04%	481
2013 Q4	$131M	Buy	15,561,779 +216,912	+1%	+$1.83M	0.04%	486
2013 Q3	$122M	Buy	15,344,867 +588,655	+4%	+$4.73M	0.04%	486
2013 Q2	$114M	Buy	+14,756,212	New	+$115M	0.04%	484

Other funds holding PDLI

SPC

Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.4% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Bank of New York Mellon's PDLI Position: Q4 2020 in Review

Bank of New York Mellon sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 486,929 shares — an estimated $1.53M sold.

Bank of New York Mellon first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $147M in Q2 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

Bank of New York Mellon reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
Bank of New York Mellon sold 486,929 PDL BioPharma, Inc. shares in Q4 2020, an estimated $1.53M.
Bank of New York Mellon first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
Bank of New York Mellon's PDL BioPharma, Inc. position peaked at $147M in Q2 2014.
33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Bank of New York Mellon's 13F filing for Q4 2020, filed 9 Feb 2021.